Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more
Biomm S.A (BIOM3) - Total Liabilities
Latest total liabilities as of September 2025: R$200.93 Million BRL
Based on the latest financial reports, Biomm S.A (BIOM3) has total liabilities worth R$200.93 Million BRL as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biomm S.A - Total Liabilities Trend (2004–2024)
This chart illustrates how Biomm S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biomm S.A Competitors by Total Liabilities
The table below lists competitors of Biomm S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ABOV Semiconductor Co. Ltd
KQ:102120
|
Korea | ₩132.48 Billion |
|
ThinTech Materials Technology Co Ltd
TWO:3663
|
Taiwan | NT$1.83 Billion |
|
Viking Tech
TWO:3624
|
Taiwan | NT$610.11 Million |
|
Ashiana Housing Limited
NSE:ASHIANA
|
India | ₹32.50 Billion |
|
Huayang Intelligent Co Ltd
SHE:301502
|
China | CN¥237.04 Million |
|
Paysign Inc
NASDAQ:PAYS
|
USA | $163.75 Million |
|
Sula Vineyards Limited
NSE:SULA
|
India | ₹5.27 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Biomm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.11 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomm S.A (2004–2024)
The table below shows the annual total liabilities of Biomm S.A from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | R$202.88 Million | -8.52% |
| 2023-12-31 | R$221.76 Million | -9.85% |
| 2022-12-31 | R$245.98 Million | -4.75% |
| 2021-12-31 | R$258.25 Million | +6.06% |
| 2020-12-31 | R$243.49 Million | +3.52% |
| 2019-12-31 | R$235.21 Million | +17.85% |
| 2018-12-31 | R$199.59 Million | -1.72% |
| 2017-12-31 | R$203.09 Million | +18.45% |
| 2016-12-31 | R$171.46 Million | +49.68% |
| 2015-12-31 | R$114.55 Million | +58.07% |
| 2014-12-31 | R$72.46 Million | +148.65% |
| 2013-12-31 | R$29.14 Million | +0.48% |
| 2012-12-31 | R$29.00 Million | +44.59% |
| 2011-12-31 | R$20.06 Million | +123.68% |
| 2010-12-31 | R$8.97 Million | -15.96% |
| 2009-12-31 | R$10.67 Million | -56.24% |
| 2008-12-31 | R$24.39 Million | +104.31% |
| 2007-12-31 | R$11.94 Million | +47.94% |
| 2006-12-31 | R$8.07 Million | -36.13% |
| 2005-12-31 | R$12.63 Million | +137.98% |
| 2004-12-31 | R$5.31 Million | -- |